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Iron therapy and cancer. Anemia in cancer patients has many mias, must have their iron status properly evaluated at
etiologies. Iron therapy clearly is indicated in patients whose appropriate intervals.
anemias are associated with iron deficiency. However, a fre-
quent cause of anemia in cancer is the “anemia of chronic
disorders,” in which, although functional iron may be low, ANEMIA OF CHRONIC DISORDERS
tissue iron remains normal or high. Administration of iron with
This review focuses on the very often encounterederythropoietin to such patients requires careful and frequent
cause of anemia in cancer, ACD. The initial observationevaluation of hematologic and iron values. Inadvertent iron
loading can contribute to deterioration of a variety of organ on ACD was reported 67 years ago by Locke, a clinical
systems, as well as to increased proliferation of neoplastic cells. pathologist [4]. His hospital laboratory possessed sam-
ples of plasma from a great variety of patients with differ-
ent illnesses. Locke et al found that specimens from
“The use of iron pills as a ‘tonic’ or for the treatment persons undergoing inflammatory defense processes are
of an undiagnosed anemia can never be condoned” [1]. hypoferremic. If patients recovered, normal levels of iron
Anemia is a common finding in cancer patients. The would return. Other research workers subsequently
condition has no dearth of etiologic factors [2]. Hemoglo- demonstrated that this profound shift in iron metabolism
is independent of dietary iron, regulated by cytokines,bin (Hb) synthesis may be impaired by nutritional defi-
and is important for host defense.ciencies (iron, folic acid, cobalamin). Erythrocyte synthe-
In addition to its occurrence in neoplastic and infec-sis may be depressed by bone marrow inadequacy
tious diseases, ACD is seen in patients with such other(metastases, pure red cell aplasia, chemotherapy, or ra-
causes of inflammation as rheumatoid arthritis, systemicdiotherapy) or, in renal failure, by erythropoietin (EPO)
lupus erythematosis, and inflammatory bowel disease, asdeficiency. Erythrocyte quantity may be reduced by
well as in persons who recently have had major traumableeding, hemolysis, or hypersplenism. Frequently, the
or surgery. Examples of chronic disorders in which ACDanemia ensues from attempts of the host to raise an
typically does not occur include diabetes mellitus, hyper-inflammatory response to defeat the neoplastic invader.
tension, asthma, ischemic heart disease, and congestiveThis condition has been termed the “anemia of chronic
heart failure.disorders” (ACD) or, more recently, the “hypoferremia
Together with the hypoferremia, features of ACD in-of inflammatory diseases.”
clude lowered values of transferrin iron saturation andManifestly, the selection of methods for correction of
transferrin iron-binding capacity, high normal or ele-anemia in cancer patients requires precise knowledge of
vated serum ferritin, and ample marrow deposits. Intesti-its cause. For some etiologies, exogenous iron is indi-
nal assimilation of iron is depressed [5]; nevertheless,cated; for others, feeding or injecting iron would be futile
serum transferrin iron receptor concentration remainsor even counterproductive. Clearly, if the particular ane-
normal [6]. This constellation of traits indicates thatmia is caused or complicated by iron deficiency, therapy
plasma iron is being lowered by a reduction in the recy-should include replenishment of the metal. However,
cling of iron to plasma from macrophages that have di-excessive amounts of exogenous iron can enhance prolif-
gested Hb from effete erythrocytes, as well as by aneration of cancer cells and depress cell-mediated immu-
elevation of the mucosal block that controls assimilationnity [3]. Accordingly, all patients who are being treated
of dietary iron.with the metal, irrespective of the cause(s) of their ane-
In normal adults, serum ferritin values are 20 to 200
ng/ml; if below 15 ng/ml, iron deficiency is present. Dur-
ing ACD, additional ferritin is formed to aid in the up-Key words: anemia of chronic disorders, iron loading, neoplastic cells,
hemoglobin, erythropoietin, metastases. regulated sequestration of the metal. Consequently, in
ACD, serum ferritin values may increase by as much as 1999 by the International Society of Nephrology
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50 ng/ml [1]. Serum ferritin values of greater than 300 anemia usually is normocytic and normochromic, mild
microcytosis and hypochromia may occur. Hematocritsng/ml in persons with or without ACD indicate that the
tissues contain excessive amounts of iron deposits. range from 20% to 40%. In ACD, the erythrocyte life
span can be moderately shortened, but the primary causeFerritin molecules that appear in serum during in-
flammation contain less iron than normal [7], presumably of the anemia is the failure of the bone marrow to in-
crease the number of circulating reticulocytes.because they have recently been synthesized. Moreover,
some of the elevated serum ferritin in cancer patients Serum EPO levels in patients with ACD, although
higher than normal, are lower than in patients with ane-may result from production of the protein by tumor cells
[8]. Note also that when ferritin is secreted by intact mia from noninflammatory disorders and are lower than
expected for the degree of anemia. However, the marrowcells, it is glycosylated; when it leaks from damaged cells,
responds to exogenous EPO. For example, a set of 10it is nonglycosylated [9].
rheumatoid arthritis patients with ACD were treated for
32 weeks with EPO plus oral iron, and their hematocrits
IRON-WITHHOLDING DEFENSE SYSTEM increased from an initial mean of 31% to a final mean
The consistently observed shift in iron metabolism in of 40.8% [14]. Likewise, in 17 patients with inflammatory
ACD is but one aspect of the extensive iron-withholding bowel disease who had chronic anemia, administration
defense system [10]. Additional features of the system of EPO plus oral iron for 12 weeks resulted in a mean
include the continuous presence of: (a) moderately un- Hb concentration that increased from an initial value of
saturated transferrin in plasma, lymphatic fluid, and cere- 8.81 6 0.27 g/dl to a final value of 10.52 6 0.41 g/dl [15].
brospinal fluid; (b) unsaturated (apo) lactoferrin in tears, In these studies, hematocrits and Hb values remained
milk, secretions of respiratory, gastrointestinal, and geni- low in patients who received oral iron without EPO.
tal tracts, and in secondary granules of neutrophils; and In a study of 17 patients with colorectal cancer, EPO
(c) ferritin in all body cells. Furthermore, when iron was given from 10 days prior to two days after surgery
withholding is up-regulated, neutrophils discharge apo- [16]. Favorable response was correlated positively with
lactoferrin into sites of inflammation. Macrophages scav- serum ferritin values (P , 0.001) and with transferrin
enge lactoferrin-acquired iron; haptoglobin and hemo- iron saturation (P 5 0.0004). When transferrin iron satu-
pexin bind extravasated Hb and hemin, and nitric oxide ration was 15% or less, hypochromic erythrocytes were
effects efflux of nonheme iron from tumor and other formed. The ability of EPO to stimulate production of
targeted cells. These and other features of the iron-with- erythrocytes normal both in size and Hb content is highly
holding defense system are essential in suppressing the dependent on availability of functional iron [17].
proliferative action of iron for neoplastic and microbial In conditions in which the anemia results from both
cell invaders, as well as in preventing the hazardous bleeding and ACD, intravenous (i.v.) iron without EPO
oxidant action of the metal toward normal cells and may be effective. In a recent study, 40 patients with
tissues. Crohn’s disease (Hb # 10.5 g/dl) were given a total of
In the inflammatory response to insult, iron-withhold- 3.5 g i.v. iron over 16 weeks [18]. In the first eight weeks,
ing defense is intensified by increased production of such half were given EPO, half placebo. In the second eight-
cytokines as interleukin-1 and interleukin-6, tumor ne- week period, EPO was increased or initiated for the
crosis factor-a (TNF-a), and interferon-g. Interleukin-1 nonresponders in each group. Seventy-five percent of
and interluekin-6 and TNF-a, formed by activated mac- the patients had a substantial response to i.v. iron alone.
rophages and other cells, can induce suppression of intes- EPO plus i.v. iron permitted a somewhat more rapid
tinal iron assimilation, reduction in recycling of iron from increase in Hb concentration as well as a lesser tendency
macrophages to plasma, and increased synthesis of ferri- to develop excessive transferrin iron saturation values
tin to sequester macrophage-retained iron [5, 11]. Inter- as compared with i.v. iron alone. However, the authors
feron-g, produced by T-lymphocytes, induces macro- noted that i.v. iron alone was more effective than EPO
phages to form nitric oxide, which causes depletion of plus oral iron in improving Hb values in Crohn’s disease
nonheme iron in tumor and other targeted cells [12]. patients. They recommended that i.v. iron saccharate, in
Inhibitory activities of nitric oxide are reversed by exoge- which the cost is only 0.8% that of EPO, be considered
nous iron [13]. first-line therapy in patients with severe anemia.
HAZARDS OF IRON LOADINGTHERAPEUTIC USE OF EPO AND IRON
A mild to moderate anemia (so-called ACD) fre- Unfortunately, unless the patient’s condition involves
bleeding, large amounts of injected iron (either as re-quently accompanies inflammatory illnesses. In chronic
conditions, the anemia develops during the first few peated quantities of 0.2 g/dose of iron as saccharate or
repeated transfusions of 0.2 g of iron per unit of wholemonths and rarely progresses thereafter. Although the
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blood) cannot be given without serious long-term conse- of 41,276 men and women followed for 14 years, 6%
quences. In the study mentioned earlier [18], i.v. iron developed cancers. Among persons in the group whose
was halted when the transferrin iron saturation value initial transferrin iron saturation value was more than
exceeded 50%. In such patients, the value returned to 60%, the relative risk (as compared with those with levels
normal within two weeks. However, it was not deter- of less than 60%) for all cancers, lung cancer, and colo-
mined how much of the excess iron had been excreted rectal cancer was 1.43, 1.51, and 3.04, respectively [25].
in bleeding or how much had been deposited in such As indicated earlier here, blood transfusions can result
vulnerable tissues as heart, liver, endocrine glands, or in iron loading. A meta-analysis of 60 studies comprising
joints. It has long been known that parenteral administra- 19,687 patients (1982 to 1994) of perioperative blood
tion of iron during episodes of inflammation does not transfusions and cancer recurrence found an adverse ef-
restore the normal level of plasma iron; instead, the fect in 28 of the reports with an increased risk of 37%
metal is deposited in the monocyte/macrophage system [26]. As a corollary, in a study of 37,795 normal blood
[19, 20]. As this system becomes saturated with iron, the
donors, the relative risk of developing cancers as com-
metal overflows into hazardous tissue sites.
pared with nondonors was 0.79 (P , 0.001) [27].The total amount of iron in a normal adult should not
Iron loading can occur not only via alimentary andexceed 4 to 5 g. By the time that the quantity of iron in
parenteral routes but also by inhalation of the metala human has increased to 15 g, sufficient organ deteriora-
contained in tobacco smoke, asbestos, and urban air par-tion has occurred to require medical assistance [21]. The
ticulates [3, 28]. Moreover, iron can be released from itsmetal contributes to a considerable panoply of diseases
normal body compartments by hemolysis or by destruc-that varies with individual patients. The association of
tion of nonerythrocytic cells that contain iron deposits.iron loading with initiation and proliferation of neo-
For example, endogenous iron released from dying cellsplasms is well established [3]. Iron is carcinogenic be-
in 40 patients given high doses of cytostatic drugs andcause of its catalytic effect on the formation of hydroxyl
total body irradiation (two weeks prior to bone marrowradicals, suppression of the activity of host defense cells,
transplantation) resulted in transferrin iron saturationand promotion of cancer cell multiplication. In both ani-
mal models and in humans, primary neoplasms develop values of 75% to 100% [29].
at tissue sites of excessive iron deposition. Patients with ACD who might be considered for ther-
During the past four decades, numerous research apy with EPO plus iron are those with Hb of less than
groups have reported, in prospective studies in animals, 10.5 g/dl, hypochromic red blood cells of more than 10%,
that administration of excessive amounts of injected or and serum EPO of less than 200 mU/ml. Sufficient EPO
oral iron increases markedly the risk of adenocarcino- plus iron should be given to maintain transferrin iron
mas, colorectal tumors, hepatomas, mammary tumors, saturation values of 25% to 35% and hematocrit values
mesotheliomas, renal tubular cell carcinomas, and sarco- of 30% to 36%. The amount of EPO required to ame-
mas [3]. In humans, these types of prospective studies liorate anemia in ACD is threefold higher than that
would be unethical. However, in large groups of humans needed in patients who have chronic renal failure with-
such as 0.5% of whites [22] and 10% of sub-Saharan out ACD [2].
Africans [23], genetic defects result in assimilation of If oral iron is employed, note that in ACD, intestinal
excessive dietary iron. In the white disease, hereditary
assimilation of the metal is dampened. If i.v. iron is
hemochromatosis, the elevation in tissue iron is associ-
used, the intervals at which transferrin iron saturationated with an increase in hepatic carcinoma of as much
is monitored should be shortened. Moreover, if canceras 200-fold; excessive frequency of nonhepatic malignan-
patients are being treated with experimental protocolscies also is observed [3, 22]. In the African disease, Afri-
that contain such inhibitors of cancer cell iron metabo-can siderosis, the incidence of hepatic carcinoma likewise
lism as gallium, iron chelators, or antibodies to trans-is quite high. For example, in one study of persons with
ferrin receptors, additional care to avoid iron overloadelevated tissue iron, an increased cancer risk of 15-fold
must be exercised.was observed [23].
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